Peter J. Mariani Purchases 20,000 Shares of Cytosorbents Co. (NASDAQ:CTSO) Stock

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) CFO Peter J. Mariani purchased 20,000 shares of the stock in a transaction dated Friday, December 13th. The shares were bought at an average price of $0.96 per share, for a total transaction of $19,200.00. Following the completion of the acquisition, the chief financial officer now owns 401,363 shares in the company, valued at $385,308.48. This represents a 5.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Cytosorbents Stock Performance

Shares of CTSO stock traded down $0.10 during trading on Monday, reaching $0.91. The company had a trading volume of 209,458 shares, compared to its average volume of 126,238. The firm's 50 day simple moving average is $0.97 and its two-hundred day simple moving average is $1.02. Cytosorbents Co. has a one year low of $0.70 and a one year high of $2.15. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The company has a market capitalization of $49.74 million, a PE ratio of -2.53 and a beta of 0.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CTSO. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Sargent Investment Group LLC boosted its holdings in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents during the 3rd quarter worth about $51,000. Finally, CM Management LLC raised its position in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CTSO shares. StockNews.com began coverage on Cytosorbents in a report on Thursday. They issued a "hold" rating on the stock. HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.